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Strengths and limitations of this study
 ► The use of several linked health-related datasets 
will provide almost complete coverage of the care 
pathways for patients with cancer from prediagnosis 
to diagnosis and treatment and to the end of life for 
those who died.
 ► Information on lifestyle factors will be included 
in the analysis separately from other patients’ 
characteristics.
 ► Both individual and neighbourhood socioeconom-
ic measures will be used in the analysis, and their 
effects will be estimated independently and jointly.
 ► Residual confounding may still exist due to missing 
data for some measured factors and lack of data 
for patients’ compliance with prescribed treatment, 
which may introduce bias through incomplete con-
trol of confounding.
 ► While the cohort may not be completely represen-
tative of the general New South Wales population 
(eg, the cohort is older and more educated), a re-
cent study indicated that there was little evidence 
of bias in the association between the area-based 
socioeconomic measure and cancer survival in this 
cohort.
AbStrACt
Introduction Socioeconomic disparities in cancer survival 
have been reported in many developed countries, including 
Australia. Although some international studies have 
investigated the determinants of these socioeconomic 
disparities, most previous Australian studies have been 
descriptive, as only limited relevant data are generally 
available. Here, we describe a protocol for a study to 
use data from a large-scale Australian cohort linked with 
several other health-related databases to investigate 
several groups of factors associated with socioeconomic 
disparities in cancer survival in New South Wales (NSW), 
Australia, and quantify their contributions to the survival 
disparities.
Methods and analysis The Sax Institute’s 45 and Up 
Study participants completed a baseline questionnaire 
during 2006–2009. Those who were subsequently 
diagnosed with cancer of the colon, rectum, lung or 
female breast will be included. This study sample will be 
identified by linkage with NSW Cancer Registry data for 
2006–2013, and their vital status will be determined by 
linking with cause of death records up to 31 December 
2015. The study cohort will be divided into four groups 
based on each of the individual education level and an 
area-based socioeconomic measure. The treatment 
received will be obtained through linking with hospital 
records and Medicare and pharmaceutical claims data. 
Cox proportional hazards models will be fitted sequentially 
to estimate the percentage contributions to overall 
socioeconomic survival disparities of patient factors, 
tumour and diagnosis factors, and treatment variables.
Ethics and dissemination This research is covered by 
ethical approval from the NSW Population and Health 
Services Research Ethics Committee. Results of the study 
will be disseminated to different interest groups and 
organisations through scientific conferences, social media 
and peer-reviewed articles.
IntroduCtIon
Even in developed countries with well-estab-
lished healthcare systems, cancer survival 
is known to vary by socioeconomic level 
of patients.1–4 In Australia, socioeconomic 
disparities in cancer survival have been 
reported over the past decade,5–11 with 
survival inequalities defined by either socio-
economic groups5 7 10 11 or rural versus metro-
politan residence.9 11 Recent studies have also 
indicated that these inequalities in cancer 
survival have either persisted12 13 or seem to 
be widening.14 15 Although the underlying 
causes of these socioeconomic inequalities 
are not well understood, the possible reasons 
can be divided into three main groups16: 
factors related to tumour characteristics at 
diagnosis, factors related to treatment access 
and quality, and patients’ characteristics. The 
latter group, including marital status, private 
health insurance coverage and comorbidities, 
may affect cancer outcomes through inter-
acting with screening and treatment access 
and decisions. Identifying these factors and 
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understanding how they may impact on cancer detection, 
treatment and survival are the crucial first steps towards 
addressing and removing these inequalities.
Several international studies have investigated the 
contributions of these determinants to survival dispari-
ties.17–19 Stage at diagnosis and treatment were found to be 
important factors contributing to the survival differences 
between population groups for prostate17 and breast 
cancer,19 whereas these factors contributed only mini-
mally to the association between socioeconomic position 
and colorectal cancer mortality.18 These results suggest 
that the reasons for survival disparities are likely to vary 
with the country’s population and health system charac-
teristics, as well as by cancer type. Also, in Australia, some 
studies using linked datasets from multiple health-related 
data sources have attempted to disentangle the possible 
reasons for the poorer cancer outcomes for patients with 
lower socioeconomic backgrounds.20 21 However, these 
Australian studies are limited due to a lack of relevant 
detailed data.20 21 To our knowledge, no study has system-
atically considered the contributions of various prog-
nostic factors, including individual lifestyle factors, on 
the disparity in cancer survival between socioeconomic 
groups in Australia.
The Sax Institute’s 45 and Up Study is an ongoing large-
scale Australian cohort study of healthy ageing of over 
266 000 individuals aged 45 years and over residing in 
New South Wales (NSW), Australia.22 Individuals joined 
the study by completing a postal questionnaire and giving 
consent for linkage of their personal information to 
routinely collected health datasets.22 Linking the 45 and 
Up Study questionnaire data with several health-related 
databases enables the examination of possible reasons 
for socioeconomic disparities in cancer survival and 
quantification of the relative contributions of patients’ 
characteristics and other prognostic factors. Information 
on many lifestyle factors was collected in the baseline 
questionnaire, such as smoking status, drinking habits, 
physical activity and body mass index (BMI). While these 
lifestyle factors have been shown to be associated with 
the risk of developing cancer,23 24 an emerging body of 
evidence suggests that these lifestyle factors may also be 
associated with prognosis for patients with prostate17 and 
colorectal cancer.25 26 Thus, in this study, we intend to 
examine potential reasons for socioeconomic disparities 
in cancer-specific survival for those who were diagnosed 
with an incident cancer (colon, rectum, lung and female 
breast) in the 45 and Up Study cohort and to quantify 
the contributions of patients’ characteristics, tumour-re-
lated factors and cancer treatments received, to dispari-
ties in cancer survival between socioeconomic population 
groups.
MEthodS
Study sample
The 45 and Up Study participants joined the study in 
2006–2009 by completing a baseline questionnaire, 
which collected information on a range of personal 
characteristics. The original aim of the study was to 
provide researchers with timely and reliable infor-
mation on a wide range of exposures and outcomes, 
which are important public health issues for the ageing 
population.22 The overall participation rate was 18%, 
and people 80+ years of age and residents of rural and 
remote areas were oversampled, and the study sample 
represents about 11% of the total NSW population aged 
45 years or older. Prospective participants were randomly 
sampled from the Medicare enrolment database held by 
the Department of Human Services (formerly Medicare 
Australia), which provides near-complete coverage of 
the population. All cohort members were followed up 
for health-related events through linkage with several 
population-wide administrative health data collections 
(figure 1). For each data collection, we are using the 
most recent data available at the time. The proposed 
study sample will include those participants who were 
diagnosed with cancer after they joined the study, as 
identified through linkage to the population-based 
cancer registry. We will include patients diagnosed with 
cancer of the colon (C18), rectum (C19-20), female 
breast (C50) or lung (C34)27 in this study. Participants 
with any prior record of cancer will be excluded, along 
with people first diagnosed at death.
data sources
45 and Up Study baseline questionnaire
The 45 and Up Study is described in detail elsewhere.22 
For this proposed study, data will be taken from the 45 
and Up Study baseline questionnaire (https://www. saxin-
stitute. org. au/ our- work/ 45- up- study/), which collected 
information on key variables such as height, weight, 
smoking status, family history of disease and levels of 
physical activity as well as a range of sociodemographic 
information. Variables to be used in this analysis are 
shown in table 1.
NSW Cancer Registry (NSWCR)
The NSWCR contains, by statutory requirement, records 
of people diagnosed with cancer in NSW since 1972.28 
Data for cancers diagnosed in 1994–2013 will be used to 
identify prevalent and incident cancer cases in the study 
cohort. The data extracted for incident cases (diagnosed 
after recruitment) will include cancer type, cancer stage 
at diagnosis, date of diagnosis and histology, as well as 
demographic variables including age at diagnosis and 
sex. NSWCR data will also be used to exclude people who 
were diagnosed with cancer before they joined the 45 and 
Up Study (prevalent cases). Incident cases can be identi-
fied up to 7 years after recruitment for those who joined 
the study in 2006 and up to 4 years for those recruited in 
2009.
NSW Admitted Patient Data Collection (APDC)
The APDC (July 2001 to June 2016) contains informa-
tion on all inpatient separations, recorded as episodes of 
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Figure 1 Health-related data collections and dates of availability. APDC, Admitted Patient Data Collection; COD-URF, Cause 
of Death Unit Record File; EDDC, Emergency Department Data Collection; MBS, Medicare Benefits Schedule; NSWCR, New 
South Wales Cancer Registry; PBS, Pharmaceutical Benefits Scheme; RBDM, New South Wales Registry of Births, Deaths and 
Marriages.
Table 1 Covariates to be included* in the analysis as 
prognostic factors for socioeconomic disparities in cancer 
survival
Patients’ 
characteristics
Tumour-related/
diagnosis-related 
factors
Treatment 
variables
a. Marital status Cancer stage at 
diagnosis
Surgery
  Private health 
insurance
Histology (varies by 
cancer type)
Systemic 
treatment
  Place of 
residence
Emergency 
presentation
Radiation 
therapy
  Comorbidity
b. Tobacco smoking
  Alcohol 
consumption
  Physical activity
  
Body mass index
*These listed covariates will only be included in the analysis model 
if they are significantly associated with survival (with p<0.05) or 
they are important confounders of the socioeconomic position and 
survival association.
care, from all public, private and repatriation hospitals in 
NSW. It captures all procedures carried out and the diag-
noses relating to the hospital episode of care. Patients 
with colon, rectal, breast and lung cancers are likely to 
use inpatient care, either for the first course of treatment, 
for complications with treatment or for other comorbid 
conditions. The APDC has been demonstrated to accu-
rately provide information on surgery received by these 
patients.29–31 Variables to be used in this analysis include 
dates of admission and separation, procedures carried 
out and diagnoses relating to the hospital episode. APDC 
data will be used to capture surgery, systemic treatment 
and radiation therapy. In combination with Medicare 
Benefits Schedule (MBS) and Pharmaceutical Benefits 
Scheme (PBS) data, almost all episodes of these types of 
treatments will be captured.31 In addition to identifying 
the cancer treatment received following diagnosis, these 
data will also be used to identify key chronic comorbid 
conditions recorded before their cancer diagnosis.
NSW Emergency Department Data Collection (EDDC)
The EDDC provides information on emergency depart-
ment (ED) presentations to NSW public hospitals. This 
information will be used to identify whether the patient’s 
diagnosis was preceded by an emergency presentation, 
which is associated with poorer survival even after taking 
into account cancer stage at diagnosis.32 Variables to 
be used include dates of arrival and departure, ED visit 
type and mode of separation. The EDDC included data 
for over 80% of all ED presentations in NSW in 2006–
2007, with near-complete coverage for metropolitan 
areas,33 and by the end of the study period the EDDC had 
near-complete coverage of all public EDs in NSW, which 
are the vast majority of the hospital EDs in NSW.
MBS and PBS
The MBS is a database of Medicare services subsidised by 
the Australian government, which covers all Australian 
citizens and permanent residents. The PBS database is 
the administrative record of government subsidised medi-
cines dispensed to all Australian citizens and permanent 
residents. The MBS and PBS data are both administered 
by the Department of Human Services. Radiation therapy 
(often conducted on an outpatient basis), systemic 
therapy and prescription medicines (chemotherapy 
and other cancer-related systemic therapies including 
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Figure 2 A flow chart of the study sample selection. DAV, Department of Veterans' Affairs; NSWCR, New South Wales Cancer 
Registry.
hormone therapy) can be identified through the MBS 
and PBS databases, respectively. Detailed names and PBS 
codes for medications relevant to these cancer types will 
be obtained from previous studies,29–31 and in addition, 
we will identify and include new medications introduced 
for these cancers since the earlier publications. In addi-
tion, dates of service (MBS) and supply (PBS) will be used 
to measure the interval between cancer diagnosis and 
treatment receipt. Data available for analysis will be from 
June 2004 to December 2016 for participants joining the 
study prior to April 2008 and from September 2005 to 
December 2016 for all other participants. In this anal-
ysis, we cannot include participants whose healthcare was 
subsidised by the Australian Government’s Department 
of Veterans’ Affairs (identified by self-report or APDC/
EDDC records), as their prescription medicines have a 
separate billing arrangement and these data are not 
available.
Death records from the NSW Registry of Births, Deaths and 
Marriages and the Australian Coordinating Registry’s Cause of 
Death Unit Record File (COD-URF)
These death records contain information about date 
of death and cause of death for residents in NSW. This 
information will be used to determine length of survival 
for each individual patient, which is the main patient 
outcome of interest in this study. Date of death infor-
mation is available to June 2017 and cause of death data 
are available to December 2015 through linkage with the 
death records. COD-URF data include the underlying 
cause of death and up to 15 contributing causes of death.
A flow chart illustrating the selection of the study 
sample with inclusions/exclusions relevant to each data 
source is presented in figure 2.
record linkage
The MBS and PBS data were linked to the 45 and Up 
Study cohort by the Sax Institute using a unique identifier 
that was provided to the Department of Human Services. 
Individual records from the NSWCR, APDC, EDDC and 
death datasets have been probabilistically linked to the 
45 and Up Study cohort by the Centre for Health Record 
Linkage (CHeReL) using a best practice approach to 
linkage while preserving privacy.34 A previous study found 
that the probabilistic linkage process was highly accurate 
with both false-positive and false-negative rates being 
<0.5%,35 and for this linkage the CHeReL reported an 
estimated false-positive linkage rate of 0.5%.
outcome variables
First, the cancer cases will be identified from the 45 and 
Up Study cohort by linkage with the NSWCR data. Then 
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their vital status and cause of death will be determined by 
linkage with the death data described above. Cancer-spe-
cific survival time will be estimated from the date of diag-
nosis to the date of death from the cancer under study 
or censored at the earlier date of death from another 
cause or at the end of follow-up (31 December 2015). To 
improve the accuracy of the estimates of cause-specific 
survival, we will use the Surveillance, Epidemiology, and 
End Results (SEER) cause-specific death classification, 
which classifies cancer deaths more accurately than the 
cause of death reported from death certificates.36
Study factors
The study factor of interest is patient’s socioeconomic 
position measured in two ways. One measure is based on 
self-reported information provided in the baseline ques-
tionnaire (individual highest level of education), and the 
other is based on neighbourhood socioeconomic status 
(nSES). Each patient will be allocated to an nSES group 
based on the Statistical Area 137 they lived in at the time 
they joined the study. The nSES will be categorised into 
four groups based on quartiles of the state distribution of 
SES scores, according to the index of relative socioeco-
nomic disadvantage from the 2011 Australian Census.38 
This index represents the average socioeconomic status 
of people living within a given neighbourhood in terms 
of level of material resources, relative to the whole popu-
lation.38 Highest education level will be categorised as: 
no school certificate, school certificate, higher school 
certificate or trade or certificate or diploma, and univer-
sity degree or higher. To examine the combined effects 
of individual SES and nSES, a joint education and nSES 
variable will be created because there may be cross-level 
interaction between individual and neighbourhood SES 
on cancer survival.39 For this variable, low education is 
defined as school certificate or below and low nSES as the 
two groups with lower score, resulting in four categories: 
‘high education and high nSES’, ‘high education and low 
nSES’, ‘low education and high nSES’, ‘low education 
and low nSES’.
Covariates
In our analysis, we will include multiple factors related 
to patients’ characteristics, tumour-related factors and 
treatment variables, which were previously found to be 
associated with cancer survival.17 25 26 40 The covariates to 
be included in this analysis are shown in table 1.
Factors related to patients’ characteristics will be 
obtained from the 45 and Up Study baseline question-
naire, except for patients’ comorbidities, which will 
be measured using the Charlson Comorbidity Index.41 
Using all available data in the APDC, comorbidities 
listed up to 5 years before the cancer diagnosis and up 
to 6 months after diagnosis will be included.42 This index 
includes 17 medical conditions (excluding prior cancer 
and prior metastatic cancer) weighted with a score of 1–6 
depending on the risk of dying associated with each one, 
so that each participant will have a total score calculated 
based on the presence of these condition scores.41 This 
index will be categorised into three groups for this anal-
ysis (0, 1 or ≥2). A sensitivity analysis will be performed by 
repeating the analysis using data on comorbidities up to 
1 year prior to the cancer diagnosis.43
Marital status will be categorised as either married/de 
facto or other status. Private health insurance status will 
be defined as yes or no, with those having private hospital 
cover or having combined cover for private hospital and 
extras being classified as having private health insurance, 
as in a previous study.44 Place of residence (based on Statis-
tical Area 1 classification) at the time of enrolment for the 
study will be divided into major cities, inner regional and 
outer regional/remote/very remote using the Australian 
Standard Geographic Classification Remoteness Struc-
ture,45 which classifies localities according to accessi-
bility to major service centres based on road distances. 
Several lifestyle factors will also be included in the anal-
ysis. Tobacco smoking (current smoker, former smoker 
who quit in the past 15 years and never smoker or former 
smoker who quit >15 years ago), alcohol consumption (0, 
1–14, >14 standard drinks per week) and physical activity 
will be defined based on self-reported data in the baseline 
questionnaire. Physical activity will be calculated using 
weighted minutes per week, adding up the number of 
minutes spent walking or being moderately active, and 
the number of minutes of vigorous activity multiplied by 
two, with the total being categorised as sedentary (0 min), 
insufficient (1–149 min), sufficient (150–299 min) or high 
(300+ minutes).46 BMI will be calculated using self-re-
ported height and weight (<18.5, 18.5–24.9, 25–29.9, 
≥30 kg/m2).47
Tumour-related or diagnosis-related factors will be 
derived from multiple data sources. Cancer stage at diag-
nosis as recorded in the NSWCR is grouped as localised, 
regional, distant or unknown based on pathology reports 
and statutory notifications to the registry.12 Tumour histo-
logical types of interest will vary by cancer type. Whether 
the patient’s diagnosis follows an emergency presenta-
tion (yes/no) will be determined by the date of diagnosis 
(from the Cancer Registry) and dates of ED arrival and 
departure (from the NSW EDDC). As there is no uniform 
definition of emergency presentation prior to cancer 
diagnosis,32 we will repeat the analyses using alternative 
binary categories of time between emergency presenta-
tion and diagnosis (0–14 days vs 15 or more days, and 
0–28 days vs 29 days or more, respectively).
Treatment information will also be derived from 
multiple data sources and be coded as yes/no based on 
any indication in any data source. First course of treat-
ment will be defined as that commencing within 6 months 
of diagnosis, based on the date of diagnosis recorded in 
the Cancer Registry data. (We will perform a sensitivity 
analysis by repeating the analyses extending to 12 months 
after diagnosis to examine the effect of the timing of 
treatment received.) Receipt of radiation therapy (yes/
no) will be determined using related information from 
the APDC and MBS data; receipt of systemic treatment 
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(yes/no) will be determined using related informa-
tion from the PBS data, MBS data and APDC; receipt 
of cancer-directed surgery (yes/no) will be determined 
from the APDC (procedures carried out and diagnoses 
relating to the hospital episode) and MBS data (specific 
procedures). More details on how this treatment informa-
tion is captured in the related data sources can be found 
in four previous publications.29–31 48
Patients will be classified as having surgical treatment if 
any procedure code International Statistical Classification 
of Diseases and Related Health Problems, Tenth Revision, 
Australian Modification (ICD10-AM) in any hospital sepa-
ration indicated surgical removal of the cancer of interest 
or if the relevant surgical procedures were claimed 
through the MBS. The date of surgery will be taken as the 
date of admission for their first surgical procedure or the 
date of service recorded in the MBS data.
Patients will be classified as having cancer-related 
systemic treatment if (1) any procedure codes for any 
hospital separation indicated administration of cancer-re-
lated systemic therapy; (2) any diagnosis codes indicated 
admission for systemic therapy or (3) PBS records indi-
cated systemic treatment was provided. The systemic 
therapy commencement date will be taken to be the first 
hospital admission date for systemic therapy or the first 
date of supply recorded in the PBS data, with hospital 
admission date taking precedence. The specific drugs of 
interest will be determined for the analysis for each cancer 
type, such as gemcitabine for lung cancer, fluorouracil for 
breast cancer and capecitabine for colon cancer.
Patients will be recorded as having received radiation 
therapy if: (1) it was indicated in the MBS dataset or (2) 
any procedure code in any hospital record indicated radi-
ation therapy.48 The radiation therapy commencement 
date will be taken to be the first date of service recorded in 
the MBS data or the date of hospital admission recorded 
in the APDC.
Statistical analysis
In this study, while more recent data for APDC, MBS/
PBS and EDDC after 2015 are available, we will only 
use data up to 2015 as cause-specific survival is only 
available up to the end of 2015. For each cancer type, 
descriptive analyses of the distribution of factors among 
SES groups of interest will be undertaken using a χ2 
test. Then, Cox proportional hazards regression49 will 
be used to examine associations between cancer-spe-
cific survival and socioeconomic position (with either 
highest nSES or those with a university degree or higher 
as the reference category). The baseline model will also 
include age at diagnosis (as a continuous variable), sex 
and year of diagnosis. The highest socioeconomic group 
will be used as the reference because that represents the 
desired survival rate for all groups to achieve.50 Then, 
four more models will be fitted sequentially with one 
group of variables added at a time (groups shown in 
table 1). First, patient factors (demographic factors 
first, then lifestyle factors) will be added to the baseline 
model (models 2a and 2b); then, tumour (cancer stage, 
histology) and diagnosis factors (emergency presenta-
tion) will be added to model 2b (model 3); finally, treat-
ment variables will be added to model 3 (model 4). For 
each model, we will include nSES and education sepa-
rately, then include them together in a single model, 
and finally we will model the joint effects of the two by 
including the combined variable. The significance of a 
single covariate or a group of covariates of interest when 
added to the previous model will be tested using a like-
lihood ratio test for the nested models. To identify the 
factors that by themselves have a significant influence 
on survival disparities, we will add these listed covariates 
individually to the baseline model (which includes age 
at diagnosis, year of diagnosis and sex). Covariates will 
only be included in the analysis model if they are signifi-
cantly associated with survival (with p<0.05), and their 
addition does not change the estimated HRs for the 
socioeconomic position variables by more than 15%.
The contribution of each covariate will be calculated 
as in a previous study by Ellis et al.40 First, total disparity 
(D0) is defined as the HR for the socioeconomic group 
with the highest HR (usually the lowest socioeconomic 
group) versus the reference group, as derived from the 
baseline model including only SES, age at diagnosis, year 
of diagnosis and sex. Then, the change (usually decrease) 
in this disparity measure with the inclusion of each group 
of additional variables will be assessed by a measure of 
the relative change in disparity, based on the percentage 
of the total disparity that is explained by the addition of 
the new covariate(s) after accounting for the covariates 
that were already in the model. The measure is defined 
as ((D− − D+)/D0)×100, in which D0 is the total disparity 
from the baseline model, D− is the disparity measure from 
the model prior to introduction and D+ is the disparity 
measure from the model after inclusion of the new 
covariate(s).
Patient and public involvement
Patient and public involvement in research is burgeoning 
in Australia, and we are still learning how best to involve 
consumers in research that is based on data analysis (and 
particularly in instances where we have not collected the 
data ourselves). Since developing this research protocol, 
we have reviewed our consumer involvement practices 
and implemented the following strategies to ensure the 
patient’s perspective is considered in our future research: 
involve a dedicated, informed consumer in our research 
team to receive input into our research activities and 
request patients’ feedback on questions we recommend 
should be incorporated into the 45 and Up Study.
dissemination
Results of the study will be disseminated widely to 
different interest groups and organisations through scien-
tific conference presentations, social media and peer-re-
viewed articles.
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dISCuSSIon
This study will provide new insights into the underlying 
reasons for survival differences between socioeconomic 
population subgroups in NSW, Australia. It is hoped that 
the findings from the study will be useful in suggesting 
and informing possible changes in health policy or service 
planning, which will ensure the best possible survival 
outcomes for all cancer patients, regardless of their socio-
economic background. Targeted interventions could 
potentially lead to a reduction (or elimination) of dispar-
ities in cancer survival between population groups, and 
thus, improved survival for the whole population. The 
proposed research aligns closely with goal 2 of the Cancer 
Institute NSW’s state-wide plan for lessening the impact 
of cancers in NSW51 and addresses one of the key areas 
relating to reducing survival disparities between popula-
tion groups. Internationally, the proposed research will 
address the need to quantify the contribution of a range 
of factors to cancer survival disparities16 and contribute to 
the literature on understanding the underlying reasons 
for such disparities.17–19
One important strength of the planned analyses is 
that we will systematically quantify the separate and 
combined contributions of multiple factors to socio-
economic disparities in cancer survival, allowing the 
identification of potential underlying reasons for the 
disparities so that appropriate interventions can be 
implemented to reduce these. Another strength of the 
study is that we can include lifestyle factors separately 
to other patients’ characteristics such as marital status, 
private health insurance status and comorbidities, 
allowing us to investigate their independent impact on 
socioeconomic disparities in cancer survival. In addi-
tion, we will use both individual and neighbourhood 
socioeconomic measures in the analysis and estimate 
their effects both independently and jointly.
This study also has some potential limitations. These 
include the potential for residual confounding (not suffi-
ciently adjusting for the measured factors due to missing 
data and measurement error), not being able to deter-
mine the appropriateness of care and having no informa-
tion on patients’ treatment choices or quality of life, or 
patients’ compliance with prescribed treatments and clin-
ical follow-up. In addition, the 45 and Up Study cohort 
is unlikely to be completely representative of the general 
population of NSW (eg, the cohort is older and more 
educated),22 although a recent study indicated there was 
little evidence of bias in association between the area-
based SES and cancer survival in this cohort.52
The methods we have developed for this planned anal-
ysis and the findings from the study will lead to a further 
programme of research including:
1. Developing appropriate intervention proposals to ad-
dress any identified reasons for the disparities in surviv-
al between population groups.
2. Evaluating the effect of the interventions by monitor-
ing outcomes specific to socioeconomic disparities.
3. Applying the methods developed to survival for other 
cancer types to obtain a broader understanding of the 
underlying reasons for survival disparities after a can-
cer diagnosis.
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